Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06349642 · ClinicalTrials.gov registry record
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
A clinical trial of Metastatic Lung Non-Small Cell Carcinoma and Metastatic Colorectal Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 324
- Enrollment target
- 3
- Study locations
NCT06349642: Recruiting study of Metastatic Lung Non-Small Cell Carcinoma and Metastatic Colorectal Carcinoma, sponsored by Mayo Clinic.
NCT06349642 is a study of Metastatic Lung Non-Small Cell Carcinoma and Metastatic Colorectal Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 324 participants, above the 69-participant average among 39 other Metastatic Lung Non-Small Cell Carcinoma trials with a reported enrollment target (370% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06349642, a study of Metastatic Lung Non-Small Cell Carcinoma and Metastatic Colorectal Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 324 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
Primary Outcome
Assessed based on pathologic complete response (pCR) during checkpoint inhibitor (CPI) treatment. Clinical non-response will be defined as non-pathological complete response. Patients who cannot have pathologic complete response determined will be excluded from the primary analysis.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Tissue Collection
Study Locations (3)
Arizona
- Mayo Clinic in Arizona - Phoenix
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2024-04-24 |
| Est. Completion | 2027-05 |
What NCT06349642 shows while recruiting
NCT06349642 is an observational study that tracks outcomes without assigning an intervention. The registered 324 participants enrollment target is mid-sized for trials with a published cap, above the 69-participant average among 39 other Metastatic Lung Non-Small Cell Carcinoma trials with a reported enrollment target (370% higher).
The record links to 10 conditions, with Metastatic Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT06349642 reports a single indexed study location in Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06349642 about?
NCT06349642 is a clinical study titled "Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform". This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
What is the current status of trial NCT06349642?
This trial is currently recruiting. The enrollment target is 324 participants. The study started on 2024-04-24. Estimated completion is 2027-05.
What conditions does trial NCT06349642 study?
This clinical trial studies the following conditions: Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Early Stage Triple-Negative Breast Carcinoma.
What interventions are being tested in trial NCT06349642?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Tissue Collection (PROCEDURE).
Who is sponsoring clinical trial NCT06349642?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06349642 being conducted?
This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Lung Non-Small Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06349642's enrollment target sits among peer trials
324 2nd of 39 the highest of 39 other Metastatic Lung Non-Small Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Lung Non-Small Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
RECRUITING · NA
-
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
RECRUITING · Phase 2
-
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI